HUTCHMED (China) Limited (HCM) RNS Announcements

Add to Alert list
Date Time Source Announcement
13 Dec 2024 07:00 AM
RNS
HUTCHMED to Receive Milestone Payment from Takeda
12 Dec 2024 07:00 AM
RNS
Breakthrough Therapy Designation in China
03 Dec 2024 10:00 AM
RNS
HUTCHMED and Innovent Announce ELUNATE Approval
29 Nov 2024 08:30 AM
RNS
Total Voting Rights
28 Nov 2024 10:32 AM
RNS
Continued Inclusion of ORPATHYS in China NRDL
22 Nov 2024 07:00 AM
RNS
FRUZAQLA® Launched in Japan by Takeda
20 Nov 2024 09:30 AM
RNS
Appointment of Independent Non-executive Director
06 Nov 2024 07:00 AM
RNS
Clinical Data to be Presented at ASH and ESMO Asia
31 Oct 2024 08:30 AM
RNS
Total Voting Rights
31 Oct 2024 08:30 AM
RNS
First Commercial Milestone Payment
21 Oct 2024 09:30 AM
RNS
Vesting of awards under the LTIP
16 Oct 2024 07:00 AM
RNS
SAVANNAH: clinically meaningful response rate
24 Sep 2024 08:00 AM
RNS
Japan Approval for FRUZAQLA
09 Sep 2024 07:00 AM
RNS
Clinical Data to be Presented at ESMO and WCLC
30 Aug 2024 09:30 AM
RNS
Total Voting Rights
30 Aug 2024 07:00 AM
RNS
Update on Fruquintinib for Gastric Cancer in China
22 Aug 2024 09:30 AM
RNS
Standard form for notification of major holdings
21 Aug 2024 09:30 AM
RNS
HUTCHMED to Host Expert Call to discuss ITP
06 Aug 2024 10:00 AM
RNS
LTIP and Share Option Scheme
31 Jul 2024 12:00 PM
RNS
2024 Interim Results and Business Updates
04 Jul 2024 07:00 AM
RNS
NDA Acceptance in China for Tazemetostat
28 Jun 2024 12:35 PM
RNS
Overseas Regulatory Announcement: Form F-3 Filing
28 Jun 2024 09:30 AM
RNS
Total Voting Rights
28 Jun 2024 09:30 AM
RNS
Blocklisting Six Monthly Return
26 Jun 2024 09:30 AM
RNS
HUTCHMED to Announce 2024 HY Financial Results
24 Jun 2024 10:30 AM
RNS
Save the Date: HUTCHMED to Present R&D Updates
24 Jun 2024 07:00 AM
RNS
European Commission Approval for FRUZAQLA
17 Jun 2024 07:00 AM
RNS
Lancet Publish Phase III ESLIM-01 Results
07 Jun 2024 07:00 AM
RNS
HUTCHMED Initiates Phase I Trial of HMPL-506
03 Jun 2024 07:00 AM
RNS
Nature Medicine Publish Phase III FRUTIGA Results
31 May 2024 09:30 AM
RNS
Total Voting Rights
24 May 2024 07:00 AM
RNS
HUTCHMED Presentations at 2024 ASCO Annual Meeting
17 May 2024 03:00 PM
RNS
Retirement of Chairman and new Chairman appointed
17 May 2024 07:00 AM
RNS
HUTCHMED Data to be Presented at EHA2024 Congress
14 May 2024 07:00 AM
RNS
HUTCHMED Initiates Phase II/III Trial with Hengrui
14 May 2024 07:00 AM
RNS
HUTCHMED Initiates Registrational Phase III Trial
10 May 2024 01:00 PM
RNS
Result of AGM
08 May 2024 09:30 AM
RNS
Directorate Change
26 Apr 2024 01:30 PM
RNS
Positive CHMP Opinion for Fruquintinib
22 Apr 2024 09:30 AM
RNS
Vesting of Awards Under the LTIP
08 Apr 2024 09:30 AM
RNS
2023 Annual Report and Notice of AGM
05 Apr 2024 09:30 AM
RNS
Data to be Presented at AACR Congress 2024
02 Apr 2024 07:00 AM
RNS
HUTCHMED and Innovent Announce NDA Acceptance
28 Mar 2024 07:00 AM
RNS
Savolitinib sNDA Accepted in China
22 Mar 2024 07:00 AM
RNS
Initiation of Registration Stage of P2/3 Trial
14 Mar 2024 09:00 AM
RNS
LTIP and Share Option Scheme
05 Mar 2024 08:30 AM
RNS
Vesting of awards under the LTIP
28 Feb 2024 12:45 PM
RNS
Publication of Form 20-F
28 Feb 2024 11:30 AM
RNS
2023 Full Year Results and Business Updates
07 Feb 2024 07:00 AM
RNS
Presentation of Phase III Data on Fruquintinib

Hutchmed China  Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) is headquartered in Hong Kong and markets its products worldwide.

It was founded in 2000 and listed in London in 2018 under the ticker HCM. 

UK 100